Nektar Therapeutics Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Nektar Therapeutics (NKTR) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $48.21 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- Nektar Therapeutics net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $48.21M.
- Nektar Therapeutics net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $22.98M.
- Nektar Therapeutics net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$80.69M, a 384.30% decline year-over-year.
- Nektar Therapeutics net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $41.97M.
- Nektar Therapeutics net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$28.81M.
- Nektar Therapeutics net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$82.40M.
- Nektar Therapeutics net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$14.34M.
- Nektar Therapeutics net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$37.57M, a 175.28% decline from fiscal 2013.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $48.21M 10-Q · filed 2018-05-10 | $71.19M derived: sum of 2 quarters · filed 2018-05-10 | -$9.50M derived: sum of 3 quarters · filed 2018-05-10 | $32.47M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $22.98M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$57.71M derived: sum of 2 quarters · filed 2018-03-01 | -$15.74M derived: sum of 3 quarters · filed 2018-03-01 | -$28.81M 10-K · filed 2018-03-01 |
| 2017-09-30 | -$80.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$38.72M derived: sum of 2 quarters · filed 2017-11-08 | -$51.79M 10-Q · filed 2017-11-08 | -$193.89M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-06-30 | $41.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $28.90M 10-Q · filed 2017-08-09 | -$113.20M derived: sum of 3 quarters · filed 2018-05-10 | -$84.82M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | -$13.07M 10-Q · filed 2018-05-10 | -$155.18M derived: sum of 2 quarters · filed 2018-05-10 | -$126.79M derived: sum of 3 quarters · filed 2018-05-10 | -$131.72M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | -$142.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$113.72M derived: sum of 2 quarters · filed 2018-03-01 | -$118.65M derived: sum of 3 quarters · filed 2018-03-01 | -$82.40M 10-K · filed 2018-03-01 |
| 2016-09-30 | $28.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $23.46M derived: sum of 2 quarters · filed 2017-11-08 | $59.70M 10-Q · filed 2017-11-08 | $52.50M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | -$4.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $31.32M 10-Q · filed 2017-08-09 | $24.12M derived: sum of 3 quarters · filed 2018-03-01 | $29.82M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $36.25M 10-Q · filed 2017-05-10 | $29.04M derived: sum of 2 quarters · filed 2018-03-01 | $34.75M derived: sum of 3 quarters · filed 2018-03-01 | -$31.25M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | -$7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$1.50M derived: sum of 2 quarters · filed 2018-03-01 | -$67.49M derived: sum of 3 quarters · filed 2018-03-01 | -$14.34M 10-K · filed 2018-03-01 |
| 2015-09-30 | $5.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$60.29M derived: sum of 2 quarters · filed 2016-11-04 | -$7.13M 10-Q · filed 2016-11-04 | -$31.94M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$65.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$12.84M 10-Q · filed 2016-08-04 | -$37.64M derived: sum of 3 quarters · filed 2017-03-01 | $2.50M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $53.16M 10-Q · filed 2016-05-04 | $28.35M derived: sum of 2 quarters · filed 2017-03-01 | $68.50M derived: sum of 3 quarters · filed 2017-03-01 | $73.80M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$24.81M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $15.34M derived: sum of 2 quarters · filed 2017-03-01 | $20.64M derived: sum of 3 quarters · filed 2017-03-01 | -$37.57M 10-K · filed 2017-03-01 |
| 2014-09-30 | $40.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $45.45M derived: sum of 2 quarters · filed 2015-11-06 | -$12.76M 10-Q · filed 2015-11-06 | -$94.91M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$52.91M 10-Q · filed 2015-08-06 | -$135.06M derived: sum of 3 quarters · filed 2016-02-29 | -$93.28M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | -$58.21M 10-Q · filed 2015-05-01 | -$140.36M derived: sum of 2 quarters · filed 2016-02-29 | -$98.59M derived: sum of 3 quarters · filed 2016-02-29 | -$51.99M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$82.15M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$40.37M derived: sum of 2 quarters · filed 2016-02-29 | $6.22M derived: sum of 3 quarters · filed 2016-02-29 | $49.91M 10-K · filed 2016-02-29 |
| 2013-09-30 | $41.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $88.37M derived: sum of 2 quarters · filed 2014-11-07 | $132.06M 10-Q · filed 2014-11-07 | |
| 2013-06-30 | $46.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | $90.28M 10-Q · filed 2014-08-01 | ||
| 2013-03-31 | $43.69M 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | $113.02M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |